KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 487-495

  Zheng, Yun ^a,b   Gery, Sigal ^b   Sun, Haibo ^b   Shacham, Sharon ^c   Kauffman, Michael ^c   Koeffler, H Phillip ^b,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Karyopharm Therapeutics   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Hepatocellular carcinoma; Xenograft; XPO1 inhibitor

Indexed keywords

EXPORTIN 1; MYC PROTEIN; PROTEIN P27; PROTEIN P53; PUMA PROTEIN; SCATTER FACTOR RECEPTOR; SELINEXOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; XPO1 GENE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDRAZINES; KARYOPHERINS; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907598197     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2495-8     Document Type: Article

References (38)

1. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317-328
2. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118-1127
3. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245-1255
4. Gauthier A, Ho M (2013) Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res 43:147-154
5. Hutten S, Kehlenbach RH (2007) CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 17:193-201 (Pubitemid 46507806)
6. Xu D, Farmer A, Chook YM (2010) Recognition of nuclear targeting signals by Karyopherin-β proteins. Curr Opin Struct Biol 20:782-790
7. Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83:1021-1032
8. Nguyen KT, Holloway MP, Altura RA (2012) The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3:137-151
9. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C (2008) Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:1733-1743 (Pubitemid 351536833)
10. Van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD (2009) The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829-1840
11. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65:153-159
12. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315
13. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Daelemans D, Sandanayake V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC (2012) Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120:4621-4634
14. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi A, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28(1):155-165
15. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M (2013) Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121:4166-4174
16. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK (2013) Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 27(12):2357-2365
17. Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM (2013) Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 98:1098-1106
18. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D (2013) Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 122(17):3034-3044
19. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horionouchi S (1999) Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96:9112-9117 (Pubitemid 29374716)
20. Newlands ES, Rustin GJ, Brampton MH (1996) Phase I trial of elactocin. Br J Cancer 74:648-649 (Pubitemid 26279064)
21. Dong X, Biswas A, Süel KE, Jackson LK, Martinez R, Gu H, Chook YM (2009) Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458:1136-1141
22. Monecke T, Güttler T, Neumann P, Dickmanns A, Görlich D, Ficner R (2009) Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324:1087-1091
23. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodiq SJ, Chook YM, Look AT (2013) Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27:66-74
24. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM (2013) Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 144:447-456
25. Hsieh JL, Wu CL, Lee CH, Shiau AL (2003) Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res 9:338-345 (Pubitemid 36109750)
26. Xu D, Chook YM, Grishin NV (2012) NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 23:3673-3676
27. Huang HC, Fu SC, Horton P, Juan HF (2013) ValidNESs: a database of validated leucine-rich nuclear export signals. Nucleic Acids Res 41:D338-D343
28. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodiq SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161:117-127
29. Senapedis W, Landesman Y, St-Martin J, Kashyap T, Plamondon L, Sandanayaka V, Shechter S, Froim D, McCauley D, Nir Williams JL, Kauffman M, Sharon S (2012) Abstract 2943: KPT-SINE (selective inhibitors of nuclear export) induce apoptosis in colon cancer cells in vitro and in vivo through nuclear localization of tumor suppressor proteins (TSPs). Cancer Res 72:2943
30. Vaseva AV, Moll UM (2009) The mitochondrial p53 pathway. Biochim Biophys Acta 1787:414-420
31. Fernando J, Sancho P, Fernández-Rodriguez CM, Lledó JL, Caja L, Campbell JS, Fausto N, Fabregat I (2012) Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 227:1319-1325
32. Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L (2012) Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene 31:4848-4858
33. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Kilsovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R (2012) Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120:1765-1773
34. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Iwami T, Kawabe T (2011) CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118:3922-3931
35. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hematology 45:938-947 (Pubitemid 46646500)
36. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70:10202-10212
37. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Nq IO, Van De Rijn M, Botstein D, Brown PO (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13:1929-1939 (Pubitemid 34651483)
38. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, Fisher R (2009) Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 15:85-94